GlaxoSmithKline (GSK) is a global pharmaceutical company with a diversified portfolio of biologics, small molecules and consumer healthcare products. In Oncology GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. The company was formed in 2000 as a result of merger between GlaxoWellcome plc and SmithKline Beecham.
- In Aug 2020, US FDA approves GSK’s BLENREP (belantamab mafodotin-blmf/GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma. BLENREP is an antibody drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa.
- GSK’s Zejula (Niraparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in multiple pivotal trials. GSK is building a robust niraparib clinical development programme by assessing activity across multiple tumor types and by evaluating several potential combinations of niraparib with other therapeutics.
Page 1 of 2
